Orbimed Advisors LLC acquired a new stake in shares of Upstream Bio, Inc. (NASDAQ:UPB - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 5,693,589 shares of the company's stock, valued at approximately $93,603,000. Upstream Bio makes up about 2.1% of Orbimed Advisors LLC's investment portfolio, making the stock its 14th largest position. Orbimed Advisors LLC owned 10.62% of Upstream Bio as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in UPB. FMR LLC acquired a new stake in Upstream Bio during the fourth quarter worth about $117,977,000. Decheng Capital LLC acquired a new stake in shares of Upstream Bio during the fourth quarter worth about $54,010,000. TCG Crossover Management LLC purchased a new position in Upstream Bio during the 4th quarter worth $44,856,000. Enavate Sciences GP LLC acquired a new stake in shares of Upstream Bio during the fourth quarter worth $40,438,000. Finally, Bain Capital Life Sciences Investors LLC purchased a new stake in shares of Upstream Bio in the fourth quarter valued at approximately $37,735,000.
Upstream Bio Price Performance
Shares of UPB opened at $9.50 on Tuesday. The firm has a 50 day simple moving average of $8.06 and a 200-day simple moving average of $13.31. Upstream Bio, Inc. has a 1-year low of $5.14 and a 1-year high of $29.46.
Upstream Bio (NASDAQ:UPB - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.02). The company had revenue of $0.57 million for the quarter, compared to analysts' expectations of $0.71 million. Equities analysts forecast that Upstream Bio, Inc. will post -4.3 EPS for the current year.
About Upstream Bio
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
